Loading…
Reported covered position: Legislative Director, Rep Bob Franks (1997-2000)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
To amend the Family and Medical Leave Act of 1993 and title 5, United States Code, to clarify that organ donation surgery qualifies as a serious health condition.
Client: CAREDX, INC. · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
To amend the Family and Medical Leave Act of 1993 and title 5, United States Code, to clarify that organ donation surgery qualifies as a serious health condition.
Client: CAREDX, INC. · Firm: CAREDX, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
2026 · third_quarter · Q3
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) -Prior authorization of molecular tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
Source: Senate LDA
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
To amend the Family and Medical Leave Act of 1993 and title 5, United States Code, to clarify that organ donation surgery qualifies as a serious health condition.
Client: CAREDX, INC. · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
District of Columbia Federal Immigration Compliance Act
Client: CAREDX, INC. · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
District of Columbia Federal Immigration Compliance Act
Client: CAREDX, INC. · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
District of Columbia Federal Immigration Compliance Act
Client: CAREDX, INC. · Firm: CAREDX, INC.
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (HR5269) -Prior authorization of molecular tests
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (HR5269) -Prior authorization of molecular tests
2026 · second_quarter · Q2
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) -Prior authorization of molecular tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2026 · first_quarter · Q1
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) -Prior authorization of molecular tests
Living Donor Protection Act (LDPA) S1522, HR4582,HR4583
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2025 · fourth_quarter · Q4
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (HR5269) -Prior authorization of molecular tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES
2025 · third_quarter · Q3
-Medicare coverage of molecular testing for solid organ allograft rejection -Medicare payment of clinical laboratory tests; implementation of Sec 216 of the Protecting Access to Medicare Act of 2014 (PL 113-93) and RESULTS Act (HR5269) -Prior authorization of molecular tests
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2025 · third_quarter · RR
Issues related to coverage and payment of laboratory testing.